Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. This class of compounds are steroid hormones produced in the brain and endocrine tissues which can [...]
Increasing numbers of peri- and post-menopausal women request “bioidentical” rather than synthetic hormones. Although there is a tendency to think of bioidentical hormones as “all-natural”, they, like synthetic hormones, are manufactured in the laboratory. In [...]
The Food and Drug Administration has approved a new progestin-only oral contraceptive called Slynd. This preparation contains the novel progestin drospirenone which is one component of the oral contraceptives (OCs) YaZ and Yasmin. (These contraceptives [...]
For decades, estrogen was used as a component of hormone replacement therapy to treat menopausal symptoms, including hot flashes, night sweats, and sleep disturbance; however, after several large, prospective studies (e.g., HERS, WHI) questioned the [...]
We commonly receive questions regarding the potential effects of oral contraceptives (birth control pills) on mood and risk for depression. Despite the prevalence of OC usage, few studies have explored the association between hormonal contraceptive [...]
According to data presented at the annual meeting of the North American Menopause Society (NAMS) in Las Vega, a growing number of perimenopausal women are asking their doctors for compounded or bioidentical hormones. Although bioidentical [...]
Women with bipolar disorder often experience fluctuating mood symptoms across the menstrual cycle, typically reporting an exacerbation of symptoms during the premenstrual phase of the cycle (Rasgon et al, 2003, 2005). Other studies have indicated [...]
Early observational studies suggested that postmenopausal hormone treatment may improve cognitive functioning in women; however, studies from the Women’s Health Initiative have shown that estrogen replacement therapy started in postmenopausal women (65 years or older) [...]
While there are concerns regarding the risks associated with prolonged use of hormone replacement, an increasing number of studies suggest that the risk may be relatively low in certain settings. A study presented this week at the Endocrine Society’s annual meeting which analyzed data from 43 randomized clinical trials suggests that menopausal hormone-replacement therapy does not appear to affect mortality either positively or negatively.
It has been suggested in prior literature that the effects of cocaine are partially modulated by the gonadal hormones, estradiol and progesterone, which may account for sex differences in the use and abuse of cocaine (Evans et al. 2002 & Jackson et al. 2006). Because previous studies have shown that women who use cocaine tend to use less of this drug during periods of high endogenous progesterone levels, as in pregnancy or during the luteal phase of the menstrual cycle, a recent study explored whether progesterone replacement could be effective in reducing cocaine use in postpartum women with a cocaine use disorder. In this recent double-blinded study performed by researchers at Yale School of Medicine, women were eligible for the study if they met DSM IV criteria for cocaine abuse or dependence in the 6 months prior to conception or during pregnancy and were within 12 weeks of delivery.